Recursion Pharmaceuticals Inc expected to post a loss of 43 cents a share - Earnings Preview

Recursion Pharmaceuticals

26/02/2025 13:32

Recursion Pharmaceuticals Inc RXRX.OQ RXRX.O is expected to show a rise in quarterly revenue when it reports  results on February 28 for the period ending December 31 2024

The Salt Lake City Utah-based  company is expected to report a 74.8% increase in revenue to $19.043 million from $10.89 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Recursion Pharmaceuticals Inc is for a loss of 43 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc is $10.00​, above​ its last closing price of $8.14. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.35
-0.35
-0.34
Beat
2.9
Jun. 30 2024
-0.40
-0.40
-0.40
Met
-0.4
Mar. 31 2024
-0.43
-0.42
-0.39
Beat
7.9​
Dec. 31 2023
-0.46
-0.45
-0.42
Beat
6.4
​​Sep. 30 2023
-0.38
-0.38
-0.43
Missed
-11.7
Jun. 30 2023
-0.38
-0.37
-0.38
Missed
-1.5​
Mar. 31 2023
-0.34
-0.35
-0.34
Beat
2.3
Dec. 31 2022
-0.31
-0.29
-0.31
Missed
-6.9

This summary was machine generated February 26 at 13:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)